垂体泌乳素瘤患者组织NR2C2、EMMPRIN水平变化及其与肿瘤侵袭性、临床预后的关系探讨  

NR2C2 and EMMPRIN levels in tissues of patients suffering from pituitary prolactinoma and their relationship with tumor invasiveness and clinical prognosis

作　　者：洪艳[1] 陈静雅 胡影[1] Hong Yan;Chen Jingya;Hu Ying(Huainan Union University,Huainan,Anhui 232000,China)

机构地区：[1]淮南联合大学,安徽淮南232038

出　　处：《齐齐哈尔医学院学报》2024年第7期628-631,共4页Journal of Qiqihar Medical University

摘　　要：目的探讨垂体泌乳素瘤组织中核受体亚家族2c成员2(NR2C2)和细胞外基质金属蛋白酶诱导因子(EMMPRIN)的水平变化及其与肿瘤侵袭性、临床预后的关系。方法选择2019年6月—2021年6月本院收治的78例垂体泌乳素瘤患者为研究对象,患者均行手术切除,术后随访时间1年。采用免疫组化法检测NR2C2和EMMPRIN表达情况,对比癌组织、癌旁组织中NR2C2和EMMPRIN表达,分析垂体泌乳素瘤患者癌组织中NR2C2和EMMPRIN表达情况与临床病理参数的关系,分析影响垂体泌乳素瘤患者预后的因素。结果癌组织中NR2C2阳性表达率高于癌旁组织(P<0.05),EMMPRIN阳性表达率低于癌旁组织(P<0.05),NR2C2、EMMPRIN表达均是预后不良的独立危险因素(P<0.05);受试者工作特征曲线(ROC)分析显示,垂体泌乳素瘤组织NR2C2、EMMPRIN两者联合预测垂体泌乳素瘤患者预后不良的曲线下面积(AUC)为0.886,高于NR2C2、EMMPRIN单独预测的AUC(Z=5.245,P=0.014;Z=3.652,P=0.028)。结论垂体泌乳素瘤患者癌组织中NR2C2和EMMPRIN表达与肿瘤侵袭性、临床预后有关,NR2C2阳性患者预后不良风险高。Objective To investigate the changes of nuclear receptor subfamily 2c member 2(NR2C2)and extracellular matrix metalloproteinase-inducing factor(EMMPRIN)levels in pituitary prolactinoma tissues and their relationship with tumor invasivity and clinical prognosis.Methods 78 patients with pituitary prolactinoma who were admitted to the hospital from June 2019 to June 2021 were enrolled as study subjects.All patients underwent surgical resection and were followed up for 1 year after surgery.The expressions of NR2C2 and EMMPRIN were detected by immunohistochemical method,and the expressions of NR2C2 and EMMPRIN in cancer tissues and adjacent tissues were compared.The relationship between the expressions of NR2C2 and EMMPRIN in cancer tissues of pituitary prolactinoma patients and clinicopathological parameters was analyzed,and the factors affecting the prognosis of patients with pituitary prolactinoma were analyzed.Results The positive expression rate of NR2C2 in cancer tissue was higher than that in paracancer tissue(P<0.05),and the positive expression rate of EMMPRIN was lower than that in paracancer tissue(P<0.05).Both NR2C2 and EMMPRIN expression were independent risk factors for poor prognosis(P<0.05).Receiver operating characteristic curve(ROC)analysis showed that the area under curve(AUC)of the combination of NR2C2 and EMMPRIN in predicting poor prognosis of patients with pituitary prolactinoma was 0.886,which was higher than the AUC predicted by NR2C2 and EMMPRIN alone(Z=5.245,P=0.014;Z=3.652,P=0.028).Conclusions The expression of NR2C2 and EMMPRIN in cancer tissues of patients with pituitary prolactinoma is associated with tumor invasiveness and clinical prognosis,and patients with positive NR2C2 have a high risk of poor prognosis.

关 键 词：垂体泌乳素瘤 核受体亚家族2c成员2 EMMPRIN 免疫组化法 

分 类 号：R736.4[医药卫生—肿瘤]